Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
151.17
Dollar change
+2.73
Percentage change
1.84
%
Index- P/E- EPS (ttm)-9.26 Insider Own1.31% Shs Outstand56.61M Perf Week3.41%
Market Cap8.56B Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float55.87M Perf Month2.89%
Income-521.07M PEG- EPS next Q-1.63 Inst Own106.38% Short Float5.27% Perf Quarter18.94%
Sales287.96M P/S29.72 EPS this Y50.20% Inst Trans3.67% Short Ratio7.60 Perf Half Y60.70%
Book/sh-2.84 P/B- EPS next Y96.96% ROA-50.22% Short Interest2.94M Perf Year37.78%
Cash/sh7.79 P/C19.39 EPS next 5Y- ROE-867.62% 52W Range64.33 - 161.00 Perf YTD20.02%
Dividend Est.- P/FCF- EPS past 5Y-19.87% ROI-99.69% 52W High-6.11% Beta0.50
Dividend TTM- Quick Ratio2.50 Sales past 5Y182.00% Gross Margin76.23% 52W Low134.99% ATR (14)4.89
Dividend Ex-Date- Current Ratio3.56 EPS Y/Y TTM14.73% Oper. Margin-171.22% RSI (14)56.15 Volatility3.23% 3.34%
Employees- Debt/Eq- Sales Y/Y TTM443.69% Profit Margin-180.95% Recom1.31 Target Price180.70
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q56.33% Payout- Rel Volume0.76 Prev Close148.44
Sales Surprise47.56% EPS Surprise14.52% Sales Q/Q534.07% EarningsFeb 07 AMC Avg Volume387.11K Price151.17
SMA202.04% SMA504.43% SMA20037.48% Trades Volume295,806 Change1.84%
Date Action Analyst Rating Change Price Target Change
Dec-20-23Initiated Jefferies Buy $150
Jun-14-23Resumed Credit Suisse Neutral $89
Apr-05-23Downgrade Oppenheimer Outperform → Perform
Apr-04-23Downgrade Morgan Stanley Overweight → Equal-Weight $151 → $108
Apr-03-23Downgrade Credit Suisse Outperform → Neutral
Oct-20-22Initiated Goldman Buy $174
Aug-30-22Resumed Berenberg Buy $166
Mar-28-22Resumed Wedbush Outperform $163
Mar-15-22Upgrade BofA Securities Neutral → Buy $148 → $161
Mar-01-22Initiated Citigroup Buy $187
Mar-22-24 12:09PM
05:27AM
Mar-17-24 08:50AM
Mar-07-24 08:14AM
Mar-04-24 08:30AM
12:00PM Loading…
Feb-15-24 12:00PM
09:40AM
Feb-08-24 10:07AM
Feb-07-24 04:01PM
08:30AM
Feb-06-24 08:46AM
Jan-31-24 04:15PM
04:01PM
Jan-29-24 08:30AM
Jan-08-24 06:01PM
08:20AM Loading…
08:20AM
Jan-07-24 05:45PM
02:00PM
Dec-28-23 04:15PM
Dec-20-23 08:30AM
Dec-19-23 08:30AM
Dec-11-23 08:30AM
Nov-29-23 04:30AM
Nov-20-23 08:00AM
Nov-15-23 08:00AM
Nov-08-23 02:07PM
Nov-07-23 04:01PM
Nov-01-23 09:55AM
Oct-31-23 08:30AM
Oct-26-23 09:35AM
08:30AM Loading…
08:30AM
Oct-16-23 04:01PM
Oct-02-23 08:00AM
Sep-23-23 07:00AM
Sep-22-23 09:24AM
Sep-15-23 08:00AM
07:27AM
Sep-14-23 12:22PM
Sep-06-23 12:11PM
11:41AM
08:21AM
Sep-05-23 04:15PM
04:03PM
04:01PM
04:01PM
Aug-28-23 09:55AM
Aug-24-23 08:30AM
07:09AM
Aug-23-23 04:48PM
Aug-15-23 08:30AM
Aug-10-23 09:55AM
Aug-08-23 06:20AM
Jul-25-23 12:19AM
Jul-23-23 08:45AM
Jun-29-23 08:10AM
Jun-17-23 05:30PM
Jun-13-23 07:00AM
Jun-07-23 08:30AM
Jun-05-23 05:30PM
May-31-23 08:30AM
May-25-23 08:30AM
May-13-23 07:00PM
May-03-23 04:15PM
06:08AM
May-01-23 03:02PM
11:45AM
07:09AM
07:00AM
Apr-27-23 04:01PM
Apr-22-23 08:11AM
Apr-13-23 08:30AM
Apr-12-23 09:18AM
Apr-06-23 04:22PM
Apr-04-23 12:43PM
Apr-03-23 04:07PM
01:10PM
12:28PM
07:05AM
07:00AM
Mar-17-23 03:35AM
Mar-10-23 08:00AM
Feb-20-23 08:08AM
Feb-18-23 07:23AM
Feb-16-23 04:01PM
Feb-07-23 08:00AM
Jan-30-23 11:46PM
Jan-08-23 05:00PM
09:30AM
Jan-04-23 08:00AM
Jan-03-23 08:00AM
Dec-26-22 08:38PM
Dec-05-22 08:00AM
Nov-22-22 08:30AM
Nov-14-22 07:00AM
05:34AM
Nov-13-22 06:15PM
Nov-11-22 12:10PM
Nov-02-22 04:01PM
Oct-31-22 08:00AM
Oct-26-22 08:00AM
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.